Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56results about How to "Diagnosis helps" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe
ActiveCN102827937ADiagnosis helpsHelp to getMicrobiological testing/measurementDNA/RNA fragmentationGenotypeClinical diagnosis
The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.
Owner:上海源奇生物医药科技有限公司
Distribution transformer integrated detection device
InactiveCN106597158AImprove efficiencyIncrease flexibilityElectrical testingDistribution transformerData management
Provided is a distribution transformer integrated detection device comprising: a mobile device, and a detection module, an integrated wiring module, an integrated controller and a central controller arranged on the mobile device, the detection module accesses the integrated controller through the integrated wiring module to realize the automatic test of a distribution transformer, and the central controller realizes the analysis and storage of the test data. The distribution transformer integrated detection device can be conveniently detached and assembled and can be conveniently checked and maintained, performs integral control and management to complete the overall test report, performs the unified data management and diagnosis analysis, can comprehensively improve the efficiency, level, and quality of the electrical test, reduces the heavy carrying workload of the equipment during the test, improves the reliability of the transformer operation and technical management level to a large extent, can safely, flexibly, rapidly and effectively complete the relevant test projects, and realizes the intensive, digitalized, intelligent, and maneuvering transformation of the transformer equipment on-site test.
Owner:SHANGHAI OUMIAO ELECTRIC INSPECTION CO LTD
Biomarker F3 for diagnosing white matter lesion and application thereof
The invention provides a biomarker for diagnosing white matter lesion and application of the biomarker. The biomarker is ceramide (m18: 1 (4E) / 24: 1 (15Z)) (Cer (m18: 1 (4E) / 24: 1 (15Z))). According to the present invention, the biological marker ceramide (m18: 1 (4E) / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavin A), cucurbitacine E (Cucurbitacine E), cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) or ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))) so as to determine whether the white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Nucleic acid label and kit for auxiliary diagnosis of Kawasaki disease
InactiveCN105821119AHigh clinical application valuePrediction of concurrent coronary artery damageMicrobiological testing/measurementDNA/RNA fragmentationPolymerase chain reactionC-reactive protein
The invention belongs to disease detection kit, and concretely relates to a kit for auxiliary diagnosis of Kawasaki disease by using miRNA as a biological label. The nucleic acid label is hsa-miR-223-3p, and the kit includes a primer subjected to a real-time quantitative polymerase chain reaction (RT-qPCR) for hsa-miR-223-3p. The kit can combine blood routine examination, high-sensitivity C reactive protein, erythrocyte sedimentation rate and cardiac ultrasonography, and is conducive to auxiliary diagnosis of Kawasaki disease and prediction damage of coronary artery.
Owner:SOOCHOW UNIV AFFILIATED CHILDRENS HOSPITAL
Biomarker F7 for diagnosing white matter lesion and application thereof
The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))). According to the present invention, the biomarker ceramide (d18: 0 / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavanin A), cucurbitacine E (Cucurbitacine E) or cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) so as to determine whether the white matter lesion exists or not; the biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Biomarker for diagnosing white matter lesion and application thereof
The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Overheating fault diagnosis method of transformer
InactiveCN105510729AHigh practical valueComprehensive failure typesElectrical testingProbability estimationTransformer
The invention relates to an overheating fault diagnosis method of a transformer. The method comprises steps of calculating basic probability distribution functions of all kinds of faults on the evidence of codeless four ratios and characteristic gas by use of a posterior probability SVM; and then according to evidence theory definition, calculating fusion results of all kinds of the results under combined effects of multi-evidence bodies for belief functions of different evidence bodies. A probability estimation module is introduced in a 'one versus one' multiclass SVM by use of a pair-wise coupling algorithm, so defects of limitations on following data processing imposed by hard decision output when a traditional SVM is solving multiclass problems are overcome and an SVM probability output problem is effectively solved. According to the invention, by fully using redundant and complementation information of chromatographic data and electric test data and applying the D-S evidence theory, correction and reliability of comprehensive diagnosis results based on multi-default characteristics are greatly improved than the diagnosis based on single-default characteristics, which facilitates diagnosis of fault types of the transformer and has practical significance for formulation of maintenance strategies of the transformer.
Owner:STATE GRID CORP OF CHINA +3
Plasma exosome tRFs marker and application thereof to breast cancer diagnosis
PendingCN110373471AImprove sensitivity and specificityIncreased sensitivityMicrobiological testing/measurementDiseaseCrowds
The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.
Owner:THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV
Mass spectrometry reagent kit and method for rapid tuberculosis diagnosis
InactiveCN101196526AAccurate identificationStrong precisionComponent separationBiological testingOrganismMass spectrography
The invention relates to a method for capturing the phthisic Proteome in biological samples by supporting the stroma with the bead and separating the bead from the samples by the magnetic separator without the centrifuged samples. Then conduct the protein fingerprinting by the analysis of mass spectrography. The reagent kit tests the sensibility and the specificity of the normal person with the tuberculosis by Double Blind Test, which are all 100percent, among which the deviant SAA A can be used as blood serum in vitro for testing the normal person, minor tuberculosis patient, recrudescent tuberculosis patient, severe tuberculosis patient and tuberculosis patient after effective treatment. The elevated deviant SAA A shows poor treatment effectiveness, severe tuberculosis and the recrudescent tuberculosis, thus being a protein fingerprinting group for early warning of the early detection on tuberculosis worsening and prediction on tuberculosis recrudescence. The method provided in the invention can be used as the reagent kit to distinguish the protein fingerprinting or mass spectrum mapping between the normal person and the tuberculosis patient. The method is correct, convenient and fast.
Owner:许洋
Reagent kit and method for judging normal person and liver cancer using magnetic bead supported matrix
InactiveCN101169417AStrong precisionDiagnosis helpsComponent separationBiological testingNormal peopleSupport matrix
The invention relates to a proteome acquiring method which utilizes the method of the bead supporting stroma to capture the liver cancer protein group in the biology samples, and utilizes the magnetic separator to separate the bead and the sample without eccentric samples, and then utilizes the matter hidden method to analyze. The invention can be used in the protein fingerprint of the normal people and the liver cancer or the reagent box of the mass spectrum polypeptide atlas. The invention is accurate, convenient and quick.
Owner:许洋
Specific autoantibody of PBC (primary biliary cirrhosis) and application
InactiveCN103044548ADiagnosis helpsAids in differential diagnosisImmunoglobulins against animals/humansBiological testingAnti-mitochondrial antibodyAntigen
The invention provides a specific autoantibody of the PBC and a corresponding antigen. RBE (relative biological effectiveness) TP (total protein) of cholangiocarcinoma cells is taken as the antigen of the specific autoantibody; an IB (immunoblotting) method is adopted to detect the serum of a PBC patient; an autoantibody aiming at protein with the molecular weight about 20kD is detected and named Sp20 antibody; and then the Sp20 antibody is separated and obtained from the serum of the PBC patient through two-dimensional electrophoresis. The invention further provides an application of the Sp20 antibody in preparation of a kit for PBC diagnosis. By means of research on the mechanism of the Sp20 antibody in PBC incidence, theoretical basis is provided for early diagnosis, early treatment and prognostic judgment of PBC patients, diagnosis for AMA (anti mitochondrial antibody)-negative PBC patients is facilitated, and differential diagnosis with other autoimmune diseases is facilitated.
Owner:PEOPLES HOSPITAL PEKING UNIV
Medical image processing method, medical image processing device, storage medium and computer equipment
PendingCN111128348AImprove accuracySupport diagnosisImage enhancementReconstruction from projectionImaging processingSign detection
The invention relates to a medical image processing method, a medical image processing device, a storage medium and computer equipment. According to the invention, during processing of a medical image, when it is detected that a first-level image structure contains abnormal signs, abnormal sign detection is continuously conducted on the second-level image structure contained in the first-level image structure, that is, abnormal sign detection is conducted on all the image structures according to the sequence from the high level to the low level, so that the abnormal detection can be comprehensive; and the target image structure containing the abnormal signs is determined based on the detection result, and then abnormal classification is performed through at least one classification model,so that the accuracy of the abnormal classification result can be enhanced, reliable abnormal category information can be obtained to support the doctor to perform further diagnosis, and the doctor can perform accurate diagnosis in the later period.
Owner:SHANGHAI UNITED IMAGING INTELLIGENT MEDICAL TECH CO LTD
FN test paper for quickly diagnosing bladder cancer and application thereof
InactiveCN101634655AGuided treatmentHigh sensitivityMaterial analysisDiseaseAntiendomysial antibodies
The invention relates to an FN test paper for quickly diagnosing bladder cancer, which comprises a substrate, a sample pad, a gold colloidal pad, a nitrocellulose membrane layer and an absorbent paper layer, wherein the substrate is sequentially covered by the sample pad, the gold colloidal pad, the nitrocellulose membrane layer and the absorbent paper layer, and the gold colloidal pad comprises a gold-labelled antibody compound combining colloidal gold and anti-urine fibronectin antibodies. The invention also discloses application of the FN test paper for quickly diagnosing the bladder cancer. The FN test paper for quickly diagnosing the bladder cancer has the advantages of high speed, high sensitivity, strong specificity, good stability, simple and convenient operation, no need of any instrument or equipment, visual and reliable result judgment, easy grasp and suitability for diagnosis of the disease of bladder cancer and self-monitoring of the condition of the disease by detection of the urine fibronectin in urine.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
Protein fingerprint method for biological sample analysis
InactiveCN1566953AAccurate resolutionQuick dimension descriptionComponent separationCharacter and pattern recognitionAnalysis dataSpectroscopy
This invention relates to a protein dactylography for analysis of biological sample. This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This method can be used to the diagnosis of cell and clinic diseases, such as tumor with accuracy, convenience and quickness.
Owner:许洋
Biomarker for diagnosing cerebral infarction and white matter lesion and application thereof
ActiveCN113447601ADiagnosis helpsComponent separationDisease diagnosisCerebral infarctionInternal medicine
The invention provides a biomarker for diagnosing cerebral infarction and white matter lesion and application of the biomarker. The biomarker is an application of galactosylceramide in preparation of a detection reagent for diagnosing cerebral infarction and white matter lesions, and the biomarker galactosylceramide is combined with glucosylceramide, beta-allopietapentaol, platyclalene, 1, 3Z, 6Z, 9Z-nonane tetraene, p-cymene, oxalic acid, 3-(stearoyloxy)-4-(trimethyl ammonium) butyrate for diagnosing cerebral infarction and white matter lesions, so the risk of suffering from cerebral infarction and white matter lesion can be judged, and the cerebral infarction and white matter lesion can be prevented in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Use of protein fingerprint method in detecting protein fingerprint of colon cancer and rectum cancer in blood
InactiveCN1595138AAccurate resolutionQuick dimension descriptionComponent separationSamples introduction/extractionAdenocarcinoma polypsAnalysis data
This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method is used to detect the protein fingerprint in the normal cell, restocarcinoma patient cell and rectal polyp patient cell.
Owner:BEIJING SELDI TECH
Cancer urine detection reagent
InactiveCN104597046ALow costSimple and fast operationMaterial analysis by observing effect on chemical indicatorPotassium iodinePrecipitation
The invention relates to in-vitro detection reagents for clinical diagnosis and in particular relates to a cancer urine detection reagent. The urine detection reagent is prepared from iodine, potassium iodide, mercury chloride, concentrated sulfuric acid and distilled water. After the test solution is dripped into the urine, the urine immediately develops color, precipitates of different colors are naturally downwards precipitated within 5-15 minutes, whether the detected patients are healthy patients or patients suffering from nephritis, benign tumors and malignant tumors can be judged by virtue of different colors developed by the solution and precipitates. According to the detection reagent disclosed by the invention, the defects in the prior art are overcome, and the detection reagent is a rapid metabolic disorder urine test reagent of a novel formula and has high stability, sensitivity and specificity and wide application range.
Owner:CHONGQING DOUHAO BIOTECH +1
Use of protein finger print method in detecting kidney cancer cell protein finger print in blood
InactiveCN1936578AAccurate resolutionQuick dimension descriptionComponent separationBiological testingKidney cancerMass Spectrometry-Mass Spectrometry
This invention relates to a protein fingerprinting using stranded chromatography catch and analysis proteins. The method identifies and detects proteins in mass spectrometry. Analysis of the data is obtained in the form of computer-readable bar code format (protein fingerprint). The invention method can be used to detect blood cells in patients with renal cell carcinoma and normal cell protein fingerprints. The method is accurate, fast and convenient.
Owner:北京赛尔迪生物医药科技有限公司
Biomarker for diagnosing cerebral infarction of white matter lesion patient and application of biomarker
ActiveCN113447599ADiagnosis helpsComponent separationDisease diagnosisPhosphatidylinositolEthanolamines
The invention provides application of a biomarker phosphatidylinositol (22: 0 / 19: 0) in preparation of a detection reagent for diagnosing cerebral infarction of a white matter lesion patient. The risk of cerebral infarction of the white matter lesion patient is judged by combining the biomarker lipophosphatidylinositol (22: 0 / 19: 0) with glucosylceramide (d18: 0 / 24: 1 (15Z)), beta-hydroxyethyl ethanolamine, tomatidine, phosphatidylserine (22: 6 / 20: 1) or decanoyl carnitine. Cerebral infarction can be prevented in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Standard reagent kit for mass spectrometry clinical diagnosis and the method
InactiveCN101165482AStrong precisionDiagnosis helpsComponent separationBiological testingMass Spectrometry-Mass SpectrometryBuffer solution
The standard substance kit is a standardization quality-controlled blood serum sampler packaged in tubule. Under -80 deg. C, the pooled serum is taken out and is diluted in U9 buffer solution in 1:2 mixing ratio; saving it at 25 deg. C. A quantification mass spectrographic analysis under the control of standardization quality-controlled O type blood serum is used for test.
Owner:许洋
Use of protein fingerprint method in detecting protein fingerprint of gastric carcinoma cell in blood
InactiveCN1595139AAccurate resolutionQuick dimension descriptionComponent separationSamples introduction/extractionAnalysis dataSpectroscopy
This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.
Owner:BEIJING SELDI TECH
Biomarkers and their applications for the diagnosis of cerebral infarction and white matter lesions
The invention provides biomarkers for diagnosing cerebral infarction and white matter lesions and applications thereof. The biomarker is the application of galactosylceramide in the preparation of detection reagents for diagnosing cerebral infarction and white matter lesions. The biomarkers Galactosylceramide combined with glucosylceramide, β‑alpipentol, arborvitene, 1,3Z,6Z,9Z‑nonanetetraene, p-cymene, oxalic acid, 3‑(stearyloxy) ‑4‑(Trimethylammonium) butyrate can be used to judge the risk of cerebral infarction and white matter lesions, and can prevent and prevent cerebral infarction and white matter lesions in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Application of end-grain cutting protein peptide A to stomach cancercell lymph node metastasis detection
InactiveCN101021508AImprove accuracyReduce areaComponent separationBiological testingGastric cancer cellMass spectrography
Owner:许洋
Transformer fault diagnosis method and system based on neural network
PendingCN114742173AEffective guidanceFast convergenceCharacter and pattern recognitionNeural learning methodsError functionFitness function
The invention discloses a transformer fault diagnosis method and system based on a neural network, and the method comprises the steps: taking a transformer fault diagnosis result as a target object, carrying out the coding of the target object, setting an initial cluster, and eliminating and updating a new group; selecting an error function calculated each time as a fitness function, initially calculating a fitness population of each population, selecting a new population and eliminating an old population; genetic operators are selected according to the probability, operator selection, crossover operators and mutation operators are carried out in sequence, and a fault diagnosis result is generated. According to the invention, intelligent diagnosis of the fault type and the fault degree of the transformer can be realized, diagnosis of the fault of the transformer is facilitated, and the method has an effective guiding effect on engineering practice.
Owner:XIAN THERMAL POWER RES INST CO LTD
Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe
ActiveCN102827937BDiagnosis helpsHelp to getMicrobiological testing/measurementDNA/RNA fragmentationABLGenotype
Owner:上海源奇生物医药科技有限公司
Use of protein fingerprint method in detecting protein fingerprint of pancreas cancer cell in blood
InactiveCN1595140AAccurate resolutionQuick dimension descriptionComponent separationSamples introduction/extractionAnalysis dataPancreas Cancers
This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.
Owner:BEIJING SELDI TECH
Use of enhanced protein fingerprint spectrum
InactiveCN1844915AAccurate resolutionQuick dimension descriptionComponent separationProtein profilingNormal cell
The invention discloses a protein fingerprint method for analyzing the protein group. It uses mass spectrography to detect the protein group, and the usable data analyzed by statistics is the bar cod (protein fingerprint) red by the computer. Said bar code can be transformed into one strengthen protein fingerprint drawing instructed by standard mass control serum; the protein can be kept by bar code (digital code) or drawing (strength protein fingerprint drawing) forever after being detected. The invention can be used to detect the protein fingerprint of normal cell and sufferer cell, with high speed and simple process.
Owner:许洋
Biomarkers and their applications for diagnosing cerebral infarction in patients with leukoencephalopathy
ActiveCN113447599BDiagnosis helpsComponent separationDisease diagnosisLeukoencephalopathyPhosphatidylinositol
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com